Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab-Reference-Cited by-同舟云学术

Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab

Published:2015-10-01 Issue:4 Volume:144 Page:570-578
ISSN:1943-7722
Container-title:American Journal of Clinical Pathology
language:en
Short-container-title:

Author:

Lee Hee Jin¹,Kim Joo Young²,Park So Yeon³⁴,Park In Ah¹,Song In Hye¹,Yu Jong Han⁵,Ahn Jin-Hee⁶,Gong Gyungyub¹

Affiliation:

1. Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea

2. Department of Pathology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea

3. Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea

4. Department of Pathology, Seoul National University College of Medicine, Seoul, Korea

5. Departments of Surgery, Asan Medical Center, Seoul, Korea.

6. Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.

Publisher

Oxford University Press (OUP)

Subject

General Medicine

Link

http://academic.oup.com/ajcp/article-pdf/144/4/570/25001128/ajcpath144-0570.pdf

Reference36 articles.

1. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

2. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease;Press;Cancer Res,1993

3. HER-2/neu oncogene protein and prognosis in breast cancer;Tandon;J Clin Oncol,1989

4. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease;Cobleigh;J Clin Oncol,1999

5. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HER2 amplification subtype intrahepatic cholangiocarcinoma exhibits high mutation burden and T cell exhaustion microenvironment;Journal of Cancer Research and Clinical Oncology;2024-08-28

2. Bispecific radioimmunoconjugates exploit receptor heterogeneity for positron emission tomography of tumors expressing HER2 and/or EGFR;iScience;2024-05

3. Navigating HER2-Low Testing in Invasive Breast Cancer: Update Recommendations for Pathologists;Journal of Personalized Medicine;2024-04-28

4. NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer;Breast Cancer Research;2024-04-22

5. HER2 evaluation for clinical decision making in human solid tumours: pearls and pitfalls;Histopathology;2024-03-05